Raleigh Capital Management Inc. Purchases 2,730 Shares of AbbVie Inc. $ABBV

Raleigh Capital Management Inc. increased its position in AbbVie Inc. (NYSE:ABBV) by 17.8% in the second quarter, Holdings Channel.com reports. The fund owned 18,091 shares of the company’s stock after purchasing an additional 2,730 shares during the period. AbbVie makes up about 1.5% of Raleigh Capital Management Inc.’s investment portfolio, making the stock its 12th largest position. Raleigh Capital Management Inc.’s holdings in AbbVie were worth $4,552,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Landaas & Co. WI ADV boosted its stake in AbbVie by 1.1% during the 2nd quarter. Landaas & Co. WI ADV now owns 5,954 shares of the company’s stock valued at $1,498,000 after purchasing an additional 66 shares during the last quarter. River Street Advisors LLC raised its stake in shares of AbbVie by 1.5% in the second quarter. River Street Advisors LLC now owns 13,777 shares of the company’s stock worth $3,467,000 after purchasing an additional 205 shares during the last quarter. Laurel Oak Wealth Management LLC raised its stake in shares of AbbVie by 6.1% in the second quarter. Laurel Oak Wealth Management LLC now owns 3,889 shares of the company’s stock worth $979,000 after purchasing an additional 224 shares during the last quarter. Evolution Wealth Management Inc. lifted its holdings in shares of AbbVie by 11.2% during the second quarter. Evolution Wealth Management Inc. now owns 735 shares of the company’s stock valued at $185,000 after purchasing an additional 74 shares in the last quarter. Finally, Greenleaf Trust lifted its holdings in shares of AbbVie by 1.6% during the second quarter. Greenleaf Trust now owns 60,700 shares of the company’s stock valued at $15,275,000 after purchasing an additional 962 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Neuroscience growth is gaining momentum: AbbVie’s neuroscience franchise delivered strong first-half growth, with Parkinson’s treatment Vyalev accelerating. Potential approval and commercialization of tavapadon could provide another growth driver in the second half of 2026. Can ABBV’s Neuroscience Drugs Drive Growth in the Second Half of 2026?
• Positive Sentiment: Post-Humira diversification remains a key bullish theme: Analysts and investors point to resilient revenue growth from AbbVie’s next-generation immunology and aesthetics portfolio. Wolfe Research upgraded AbbVie on pipeline strength and valuation, while BNP Paribas Exane also expects the stock to rise. Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Positive Sentiment: Recent operating performance supports the growth case: AbbVie’s reported first-quarter 2026 revenue increased 12.4% year over year, while adjusted EPS exceeded internal expectations despite an acquired research-and-development charge. Could AbbVie Inc. Post-Humira Transformation Drive the Next Phase of Growth?
• Neutral Sentiment: Pipeline updates add potential but remain clinical-stage catalysts: AbbVie is expanding Alzheimer’s research with ABBV-1758 and studying Rinvoq against Humira in rheumatoid arthritis, while real-world China data for upadacitinib in atopic dermatitis could help reinforce Rinvoq’s commercial position. AbbVie Steps Deeper Into Alzheimer’s
• Negative Sentiment: Risks include valuation and pipeline uncertainty: A comparison with Bristol-Myers Squibb highlighted that AbbVie trades at a considerably richer valuation. Separately, the partners clarified a setback in the Phase 3 epcoritamab lymphoma study, and Erste Group Bank lowered its AbbVie earnings estimates—both potential sources of caution. Could AbbVie Win as Genmab Faces a New Regulatory Test for Epcoritamab?

AbbVie Stock Performance

AbbVie stock opened at $249.20 on Friday. The stock has a market cap of $440.29 billion, a PE ratio of 70.40, a price-to-earnings-growth ratio of 0.83 and a beta of 0.30. AbbVie Inc. has a one year low of $190.75 and a one year high of $267.47. The stock has a fifty day moving average of $244.94 and a 200 day moving average of $226.12.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts predict that AbbVie Inc. will post 14.07 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio is 195.48%.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Cantor Fitzgerald lifted their price objective on AbbVie from $265.00 to $285.00 and gave the stock an “overweight” rating in a report on Monday, August 3rd. Morgan Stanley restated an “overweight” rating and set a $296.00 target price on shares of AbbVie in a research note on Monday, August 3rd. Evercore set a $235.00 price target on shares of AbbVie in a report on Friday, May 15th. UBS Group lifted their price target on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Monday, July 13th. Finally, Piper Sandler reissued an “overweight” rating and set a $298.00 price objective on shares of AbbVie in a report on Tuesday, June 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $275.50.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.